Replies to post #57727 on PharmaCyte Biotech Inc (PMCB)

[BioInvestor4]

I wish I could afford the number of shares you boys hold! I bought in 506K shares in June at 6 cents all at once. Ready to add more! I've done all the DD... only up from here. Look at all the catalysts yet to come, and probably one next week

[$Pistol Pete$]

$PMCB agreed it is always a great entry at this level

Go $PMCB

[rudygerner]

It should perform. For those catching up, here is a quick summary:

Both previous clinical trials in pancreatic cancer showed no adverse treatment-related side effects. Both previous trials used capsules which were only partially filled. The first trial used a dose of ifosfamide of 1 g/m2 while the second trial used a dose of 2 g/m2. The smaller dose was more efficacious. Also, both trials only used two cycles of ifosfamide.

The upcoming trial will be using full capsules with unlimited cycles of ifosfamide (until the patient no longer benefits). The dose of ifosfamide in the upcoming trial will be the smaller dose of 1 g/m2. This is important for both the median survival rate and tumor shrinking effectiveness because our Cell-in-a-Box® capsules can stay in the human body for up to two years while remaining completely bioinert (no immune response from the body). The longer the capsules can stay in the body, the more time the capsules have to shrink the tumor (to make a non-operable tumor become operable) while also increasing the median survival rate.

Here's where it gets good: Abraxane received FDA approval and it elicited treatment-related adverse events of Grade 3 or higher. Our Cell-in-a-Box® with low dose ifosfamide to treat pancreatic cancer elicits no treatment-related side effects. Furthermore, our treatment has a better median survival rate than both gemcitabine and Abraxane, shrinks tumors to make inoperable tumors become operable and also increases the quality of life for the patients. We have the superior treatment, highly likely to attain FDA Breakthrough Therapy and Fast Track designation imo.